How many Eliquis biosimilars are approved?

Drug Landscape tracks 6 approved Eliquis biosimilars across global regulators. 0 additional applications are filed and 1 are in Phase 3.

Is Eliquis still patent-protected?

All tracked patents on Eliquis have expired in tracked territories.

What is a biosimilar?

A biosimilar is a biological medicine highly similar to an already-approved reference biologic (the originator), with no clinically meaningful differences in safety, purity, or potency. Approved via abbreviated regulatory pathways once the originator's data exclusivity and patents expire.

Last reviewed 2026-06-10 · How we verify

Eliquis biosimilars

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Complete Eliquis (apixaban) biosimilar landscape: 6 approved biosimilars, 0 filed, 1 in Phase 3. Sponsor, approval status, first approval date, and patent timeline for the originator.

6 approved 0 filed 1 Phase 3 All key patents expired

About Eliquis

Eliquis (apixaban) — originally marketed by Bristol-Myers Squibb. Class: Factor Xa inhibitor. Target: Factor Xa (FXa). Area: Cardiovascular. First approved 2012-01-01.

Approved biosimilars (6)

Biosimilar	Sponsor	Phase	First approval
APIXABAN		marketed	2011-01-01
Apixaban 2.5 mg	Janssen Research & Development, LLC	marketed
Apixaban steady-state	Universitaire Ziekenhuizen KU Leuven	marketed
Apixaban single dose	Universitaire Ziekenhuizen KU Leuven	marketed
Apixaban vs. DAPT	DR. XAVIER FREIXA	marketed
Apixaban 2.5 milligram	McMaster University	marketed

Filed biosimilars under regulatory review (0)

No biosimilars currently under regulatory review.

Phase 3 biosimilars (1)

Biosimilar	Sponsor	Phase	First approval	Country
Apixaban Oral Tablet [Eliquis]	Hadassah Medical Organization	phase 3

Originator patent timeline

Active patents (0)

No active patents tracked.

Expired patents (0)

No expired patents tracked.

Subscribe to biosimilar updates

Every regulatory action on Eliquis or any of its biosimilars:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing